Please provide your email address to receive an email when new articles are posted on . Of the seven treatments evaluated, only one was a triple-combination therapy. Result showed the fixed-dose, ...

As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...

Bullous pemphigoid is a rare autoimmune disease that affects your skin. It’s a chronic disease that causes itchy, fluid-filled blisters to form all over your body. Although people of all ages, ...

A novel topical gene therapy healed most lesions among patients with dystrophic epidermolysis bullosa, a rare genetic blistering skin disease, the GEM-3 trial showed. Topical administration of ...

Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

Linear IgA bullous dermatosis (LABD) is an autoimmune disease that causes blisters. People with LABD can develop blisters in the skin and the mucous membranes in their mouth, genitals, and eyelids.

Pemphigus vulgaris is a rare autoimmune condition that causes painful blistering on the skin and mucous membranes. These blisters commonly appear in the mouth and are prone to bursting easily, which ...

A new study published in the journal of JID Innovations revealed that pemphigus is not significantly associated with an ...

The FDA approved Krystal Biotech Inc's KRYS Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa (DEB). Epidermolysis ...

BOSTON (Reuters) - Four weekly injections of the cancer drug Rituxan may be enough to provide a long-term cure for a rare but potentially fatal skin disorder characterized by blistering lesions that ...